It has been recently revealed that the two US studies, which were temporarily suspended due to its controversial material, have now been allowed by a US panel for publication.
Both the studies have been funded by the US government, but were in news for creating a strain that can spread bird flu in ferrets. However, both the studies have now been altered and are now suitable for publication.
The US National Security Advisory Board for Biotechnology (NSABB) confirmed that both the studies have been revised as per their instructions. They further affirmed that both the studies were put on halt for publication in last December at the time when it was realized that strain can be used by terrorists to threat the country and other parts of the world.
A series of discussions took place, which differed in opinions, as some experts said that research is a tool of exploration and it is right of readers to know the new developments. However, another set of experts were of the view that new strains can act as threat for the entire world.
Both the researches’ were not meant to be published in same journal. One of the researches was meant to be published in Science, and other was meant for Nature. But the nature of both the researches was similar, as both have developed new strains of dangerous H1N1virus.
Panel member Michael Osterholm said that they are concerned about the amateur readers. He further affirmed, "I worry about the garage scientist, about the do-your-own scientist, about the person who just wants to see if they can do it”.
Recently, a meeting has also been conducted at Geneva in which both the researches were being discussed. The meeting concluded that both the journals will publish either revised editions or parts of the studies.
- Postage Prices will Decrease from Sunday; USPS not too Happy About It
- Marriott and Starwood Hotels & Resorts Worldwide Inc Shareholders Approve to $14.41 Sales Deal
- UK plan to impose additional tax on sugary drinks
- Obesity during pregnancy may increase risk of very ‘large babies’
- Dropping Sales at Gap’s Key Brands hurt the Company’s Shares